Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Receives Positive Final NICE Guidance On Multaq

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.

You may also be interested in...



Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis

U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.

Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis

U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.

Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

The latest appraisals from NICE include the rejection of Herceptin use in gastric cancer but give positive recommendations to RoActemra and TNF-inhibitors in rheumatoid arthritis.

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel